Monopar Therapeutics (MNPR) Treasury Shares (2020 - 2026)
Monopar Therapeutics (MNPR) posted Treasury Shares of $175634.0 for Q4 2025, up 53.24% sequentially from $114610.0 in Q3 2025, and up 331.12% YoY from $40739.0 in Q4 2024.
Monopar Therapeutics (MNPR) Treasury Shares (2020 - 2026) Analysis & Trends
Monopar Therapeutics has reported Treasury Shares for 6 years, with the latest figure at $175634.0 in Q4 2025.
- Quarterly Treasury Shares rose 331.12% year-over-year to $175634.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $175634.0 (up 331.12% YoY) and the FY2025 annual result came in at $175634.0, up 331.12% from the prior year.
- Treasury Shares rose to $175634.0 in Q4 2025 per MNPR's latest filing, from $114610.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $525565.0 in Q2 2023 and troughed at $40739.0 in Q4 2024.
- A 5-year average of $218852.2 and a median of $149364.0 in 2025 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2024 and 2025: Treasury Shares sank 89.86% in 2024, then surged 331.12% in 2025.
- Over 5 years, Treasury Shares stood at $111462.0 in 2021, then slumped by 51.08% to $54529.0 in 2022, then soared by 53.34% to $83617.0 in 2023, then sank by 51.28% to $40739.0 in 2024, then soared by 331.12% to $175634.0 in 2025.
- According to Business Quant data, Treasury Shares over the past three periods registered $175634.0, $114610.0, and $128408.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 144,834.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144,834.00 |
| Jun 30, 2026 | 144,834.00 |
| Dec 31, 2025 | 175,634.00 |
| Dec 31, 2025 | 175,634.00 |
| Sep 30, 2025 | 114,610.00 |
| Sep 30, 2025 | 114,610.00 |
| Jun 30, 2025 | 128,408.00 |
| Jun 30, 2025 | 128,408.00 |
| Mar 31, 2025 | 149,364.00 |
| Mar 31, 2025 | 149,364.00 |
| Dec 31, 2024 | 40,739.00 |
| Dec 31, 2024 | 40,739.00 |
| Sep 30, 2024 | 47,843.00 |
| Sep 30, 2024 | 47,843.00 |
| Jun 30, 2024 | 349,154.00 |
| Jun 30, 2024 | 349,154.00 |
| Mar 31, 2024 | 366,534.00 |
| Mar 31, 2024 | 366,534.00 |
| Dec 31, 2023 | 83,617.00 |
| Dec 31, 2023 | 83,617.00 |